A citation-based method for searching scientific literature

Michael V Genuardi, Paul J Mather. Ther Adv Cardiovasc Dis 2021
Times Cited: 3







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
David D Berg, Pardeep S Jhund, Kieran F Docherty, Sabina A Murphy, Subodh Verma, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez,[...]. JAMA Cardiol 2021
21
66

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
66


Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
66


Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come.
Chun-Song Hu, Qing-Hua Wu, Da-Yi Hu, Tengiz Tkebuchava. Chronic Dis Transl Med 2018
5
33

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell, Julie A Lovshin, David Z I Cherney. Circulation 2017
208
33

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu. Front Cardiovasc Med 2021
3
33

Involvement of NADPH oxidases in cardiac remodelling and heart failure.
Alexander Sirker, Min Zhang, Colin Murdoch, Ajay M Shah. Am J Nephrol 2007
63
33

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
283
33

Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J V McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. N Engl J Med 2014
33

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
Hiroaki Kusaka, Nobutaka Koibuchi, Yu Hasegawa, Hisao Ogawa, Shokei Kim-Mitsuyama. Cardiovasc Diabetol 2016
77
33

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.
Javed Butler, Muhammad Shariq Usman, Muhammad Shahzeb Khan, Stephen J Greene, Tim Friede, Muthiah Vaduganathan, Gerasimos Filippatos, Andrew J Stewart Coats, Stefan D Anker. ESC Heart Fail 2020
19
33

Ketone bodies for the starving heart.
P Christian Schulze, Jasmine M F Wu. Nat Metab 2020
6
33

Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure.
Ting Liu, Eiki Takimoto, Veronica L Dimaano, Deeptankar DeMazumder, Sarah Kettlewell, Godfrey Smith, Agnieszka Sidor, Theodore P Abraham, Brian O'Rourke. Circ Res 2014
104
33

Heart disease and stroke statistics--2015 update: a report from the American Heart Association.
Dariush Mozaffarian, Emelia J Benjamin, Alan S Go, Donna K Arnett, Michael J Blaha, Mary Cushman, Sarah de Ferranti, Jean-Pierre Després, Heather J Fullerton, Virginia J Howard,[...]. Circulation 2015
33

Heart failure in the last year: progress and perspective.
Daniela Tomasoni, Marianna Adamo, Markus S Anker, Stephan von Haehling, Andrew J S Coats, Marco Metra. ESC Heart Fail 2020
10
33

Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis.
Diego Chambergo-Michilot, Astrid Tauma-Arrué, Silvana Loli-Guevara. Int J Cardiol Heart Vasc 2020
7
33

Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.
Salva R Yurista, Herman H W Silljé, Harry van Goor, Jan-Luuk Hillebrands, Hiddo J L Heerspink, Luiz de Menezes Montenegro, Silke U Oberdorf-Maass, Rudolf A de Boer, B Daan Westenbrink. Cardiovasc Drugs Ther 2020
9
33

Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo.
J i Oyama, H Shimokawa, H Momii, X Cheng, N Fukuyama, Y Arai, K Egashira, H Nakazawa, A Takeshita. J Clin Invest 1998
87
33

SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects.
Carolyn S P Lam, Chanchal Chandramouli, Vineeta Ahooja, Subodh Verma. J Am Heart Assoc 2019
64
33


Plasma cytokine parameters and mortality in patients with chronic heart failure.
M Rauchhaus, W Doehner, D P Francis, C Davos, M Kemp, C Liebenthal, J Niebauer, J Hooper, H D Volk, A J Coats,[...]. Circulation 2000
601
33

Glucose Metabolism in Cardiac Hypertrophy and Heart Failure.
Diem H Tran, Zhao V Wang. J Am Heart Assoc 2019
46
33

Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors.
Sarayut Lahnwong, Siriporn C Chattipakorn, Nipon Chattipakorn. Cardiovasc Diabetol 2018
64
33

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
33

Heart Failure Awareness 2002--and beyond.
Barry H Greenberg. J Card Fail 2002
8
33

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Karen M Hallow, Gabriel Helmlinger, Peter J Greasley, John J V McMurray, David W Boulton. Diabetes Obes Metab 2018
182
33

Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, Urszula Masiukiewicz, Richard Pratley, Sam Dagogo-Jack, Robert Frederich, Bernard Charbonnel, James Mancuso, Weichung J Shih,[...]. Circulation 2020
58
33



Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
289
33

SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
Diogo Santos-Ferreira, Pedro Gonçalves-Teixeira, Ricardo Fontes-Carvalho. Cardiology 2020
8
33



Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Jessica A Starr, Nathan A Pinner, Katelin M Lisenby, Alyssa Osmonson. Pharmacotherapy 2021
2
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
33

Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
John J V McMurray, David C Wheeler, Bergur V Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, Glenn M Chertow, Fan Fan Hou, Peter Rossing, C David Sjöström,[...]. JACC Heart Fail 2021
1
100

Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.
Giuseppe M C Rosano, Brenda Moura, Marco Metra, Michael Böhm, Johann Bauersachs, Tuvia Ben Gal, Stamatis Adamopoulos, Magdy Abdelhamid, Vasiliki Bistola, Jelena Čelutkienė,[...]. Eur J Heart Fail 2021
7
33

Neurohormonal Blockade in Heart Failure.
Thomas G von Lueder, Dipak Kotecha, Dan Atar, Ingrid Hopper. Card Fail Rev 2017
23
33

Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
Xiao-Dong Zheng, Qiang Qu, Xing-Yu Jiang, Zhong-Yuan Wang, Cheng Tang, Jin-Yu Sun. Am J Cardiovasc Drugs 2021
2
50

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Jawad H Butt, Kieran F Docherty, Mark C Petrie, Morten Schou, Mikhail N Kosiborod, Eileen O'Meara, Tzvetana Katova, Charlotta E A Ljungman, Mirta Diez, Modele O Ogunniyi,[...]. JAMA Cardiol 2021
4
33

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
Kieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, David L DeMets, Marc S Sabatine, Olof Bengtsson,[...]. Eur Heart J 2020
69
33


Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
233
33



The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Filipe Ferrari, Vítor M Martins, Rafael S Scheffel, Anderson D da Silveira, Marcelo Trotte Motta, Emilio H Moriguchi, Raul D Santos, Ricardo Stein. Ann Pharmacother 2021
3
33

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
James P Curtain, Kieran F Docherty, Pardeep S Jhund, Mark C Petrie, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine,[...]. Eur Heart J 2021
7
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.